Principal Investigators



    Charité - Universitätsmedizin Berlin

    Contact information of lead PI



    Title of project or programme

    Randomized, controlled study on the use of simvastatin in mild cognitive disorders

    Source of funding information

    Federal Ministry of Education and Research (BMBF)

    Total sum awarded (Euro)

    € 3,996,098

    Start date of award


    Total duration of award in years


    The project/programme is most relevant to:

    Alzheimer's disease & other dementias


    Research Abstract

    Purpose: Probands with MCI are at high risk to develop Alzheimer´s dementia (AD). Simvastatin may lower the production of Amyloid, a hallmark of AD in the brain. The primary hypothesis of the study is that 60 mg Simvastatin significantly reduces the Clinical Dementia Rating -Sum of boxes (CDR-SOB) in individuals with MCI as compared to MCI receiving placebo or 20 mg Simvastatin

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: Germany
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF